Media stories about Allergan (NYSE:AGN) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Allergan earned a news impact score of 0.06 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.3422532644164 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Why Did Allergan Abandon the Shire Hunt? (gurufocus.com)
- Allergan Presents Data at the Annual Meeting of the Association of Research in Vision and Ophthalmology (ARVO … (prnewswire.com)
- Why Earnings Season Could Be Great for Allergan (AGN) (finance.yahoo.com)
- Allergan launches intranasal neurostimulation device, TrueTear (healio.com)
- Allergan (AGN) Expected to Announce Earnings of $3.36 Per Share (americanbankingnews.com)
AGN stock traded up $3.41 during midday trading on Thursday, reaching $160.53. 3,275,068 shares of the company were exchanged, compared to its average volume of 3,201,403. The company has a current ratio of 1.16, a quick ratio of 1.06 and a debt-to-equity ratio of 0.38. Allergan has a 1-year low of $142.81 and a 1-year high of $256.80. The stock has a market cap of $54,654.34, a P/E ratio of 9.82, a PEG ratio of 1.12 and a beta of 1.18.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th were issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.79%. This is a boost from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend was Tuesday, February 27th. Allergan’s payout ratio is presently 17.61%.
A number of research analysts recently issued reports on the stock. Cantor Fitzgerald set a $191.00 price target on shares of Allergan and gave the stock a “hold” rating in a research note on Thursday, April 12th. Citigroup reiterated a “buy” rating and issued a $200.00 price target (down previously from $220.00) on shares of Allergan in a research note on Tuesday. Vetr downgraded shares of Allergan from a “buy” rating to a “hold” rating and set a $171.99 price target for the company. in a research note on Tuesday, April 17th. Credit Suisse Group set a $215.00 price target on shares of Allergan and gave the stock a “buy” rating in a research note on Sunday. Finally, Stifel Nicolaus initiated coverage on shares of Allergan in a report on Tuesday, April 17th. They set a “hold” rating and a $192.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $220.23.
In other Allergan news, insider Maria Teresa Hilado bought 895 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were acquired at an average cost of $167.39 per share, with a total value of $149,814.05. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was acquired at an average cost of $143.42 per share, for a total transaction of $129,078.00. The disclosure for this purchase can be found here. Insiders bought a total of 8,095 shares of company stock worth $1,258,081 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.
Allergan Company Profile
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.